参考文献/References:
[1] 陈旭,胡乐,楼龙泉,等.乳腺癌患者早期骨转移的危险因素分析[J].中华乳腺病杂志,2020,14(2):98-103.[2] 滕小艳,魏丽荣,夏前林,等.肺癌骨转移分子机制及相关分子标志物临床意义的研究进展[J].国际骨科学杂志,2020,41(3):138-142.[3] 王磊,孙俊英.血清NTx和ICTP检测在乳腺癌骨转移中的临床意义[J].陕西医学杂志,2014,43(2):208-211.[4] Lang J L, Zhao Q, He Y D, et al.Bone turnover markers and novel biomarkers in lung cancer bone metastases [J]. Biomarkers, 2018, 23(4): 1-33.[5] 刘康其,周海中.放射性药物联合双膦酸盐类药物治疗肿瘤骨转移研究现状[J].国际放射医学核医学杂志,2019,43(2):166-170.[6] Xin Y, Han B H, Wu J, et al.Diagnostic value of bone metabolic markers ICTP and BAP in lung cancer patients with bone metastases [J]. Chin J Lung Cancer, 2010, 13(10): 947-53.[7] 张辉,张阳.恶性肿瘤骨转移性疾病治疗的进展[J].中国医疗前沿,2010,5(5):14,16.[8] Jung K, Lein M.Bone turnover markers in serum and urine as diagnostic, prognostic and monitoring biomarkers of bone metastasis [J]. Biochim Biophys Acta, 2014, 18(46): 425-438.[9] Joerger M, Huober J.Diagnostic and prognostic use of bone turnover markers [J]. Cancer Res, 2012, 192:197-223.[10] Ottewell P D.Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone [J]. Endocr-Relat Cancer, 2014, 21(5): 769-781.[11] Tamiya M, Suzuki H, Kobayashi M, et al.Usefulness of the serum cross-linked N-telopeptide of type I collagen as a marker of bone metastasis from lung cancer [J]. Med Oncol, 2015, 29(1): 215-218.[12] 李淼沅,袁润强,陈业辉.前列腺癌并骨转移的治疗新进展[J].中华腔镜泌尿外科杂志,2018,12(2):73-75.[13] 杨峻峰,王剑松.前列腺癌骨转移治疗的新进展[J].现代泌尿生殖肿瘤杂志,2012,4(2):121-124.[14] 赵瑞,李鸣.Ⅰ型胶原交联氨基末端肽在前列腺癌骨转移诊断中的意义[J].现代泌尿生殖肿瘤杂志,2010,2(5):234-236.[15] 陈昊,何屹,候岩松,等.血清骨性标记物NTx和BALP与前列腺癌骨转移的关系及临床意义[J].临床肿瘤学杂志,2016,21(12):1111-1113.[16] 张作艳,关泉林,赵达.骨代谢标记物在实体瘤骨转移诊断中的临床意义[J].实用癌症杂志,2013,28(5):486-488.[17] 邓立春,姜藻,沈伟生,等.血清NTx、BSP和PSA检测在前列腺癌骨转移诊断中的意义[J].现代医学,2013,41(8):546-549.[18] Kong P, Yan J, Liu D, et al.Skeletal-related events and overall survival of patients with bone metastasis from non small cell lung cancer-a retrospective analysis [J]. Medicine(Baltimore), 2017, 96(51): e9327.[19] Wang H, Zhang Y, Zhu H, et al.Risk factors for bone metastasis in completely resected non-small-cell lung cancer[J]. Future Oncol, 2017, 13(8): 695-704.[20] 高志棣,考军,周文丽,等.UNTX水平检测在监测肺癌骨转移中的价值[J].实用癌症杂志,2007,22(2):167-170.[21] 乔丹,王智煜,文孝婷,等.血清-NTx对肺癌、乳腺癌患者诊断骨转移及预后评价价值的Meta分析[J].临床肿瘤学杂志,2015(3):212-216.[22] Liu B, Zhao Y, Yuan J, et al.Elevated n-telopeptide as a potential diagnostic marker for bone metastasis in lung cancer: a meta-analysis [J]. PLoS One, 2017, 12(11): e0187860.[23] Huang J D, Gu T J, Ying J.A meta-analysis survey of appropriate bone turnover markers in the detection of bone metastasis in lung cancer [J]. Int J Clin Oncol, 2017, 22(6): 1015-1025.[24] 张世强,陈冬波,王保庆,等.肺癌患者血清NTx、ICTP和BAP水平与骨转移的相关性研究[J].临床肿瘤学杂志,2011,16(6):534-537.[25] 吴琼,马海洋,张明明,等.多因素联合对于肺癌骨转移的诊断价值[J].中国医学导报,2018,15(16):55-58.[26] Wu C J, Ma L X, Liu J J, et al.Clinical significance of combined detection of urine NTX and serum ICTP for breast cancer patients with bone metastases [J]. Chin J Oncol, 2016, 38(9): 693-697.